-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 17, Livzon Pharmaceutical Group submitted a clinical application for a new class 1 chemical drug LZ001 tablet, which is the first class 1 new drug declared by the company this year
.
Looking back on the previous years, after Livzon won the approval for the new category 1 drug of ilaprazole enteric-coated tablets in 2007, it also won the approval for the new category 2 drug of ilaprazole sodium for injection in 2017.
The performance of innovative drugs in the market has risen step by step, and has now become a large variety of more than 2 billion.
Livzon's re-attack on innovative drugs for chemical drugs has attracted market attention
.
.
Looking back on the previous years, after Livzon won the approval for the new category 1 drug of ilaprazole enteric-coated tablets in 2007, it also won the approval for the new category 2 drug of ilaprazole sodium for injection in 2017.
The performance of innovative drugs in the market has risen step by step, and has now become a large variety of more than 2 billion.
Livzon's re-attack on innovative drugs for chemical drugs has attracted market attention
.
Picture 1: Livzon's latest product status
Source: CDE official website
It is reported that LZ001 tablets are a kind of ROS1/NTRK/ALK multi-kinase small molecule inhibitor obtained by Livzon through Zhejiang Tongkang Medicine in 2020 (initial name is TY2136b project).
At that time, the pre-clinical research and development fee and down payment of this transaction The total amount of funds and milestone payments reached 159 million yuan
.
At that time, the pre-clinical research and development fee and down payment of this transaction The total amount of funds and milestone payments reached 159 million yuan
.
Pre-clinical studies have shown that TY-2136b has excellent curative effects on multiple targets of ROS1/NTRK/ALK.
It can also effectively inhibit drug-resistant gene mutations and effectively solve many unmet clinical needs
.
In addition, according to Dr.
Li Jun, Chief Scientific Officer of Homo Health, TY-2136b also has a certain ability to penetrate the blood-brain barrier, which has potential advantages for patients with brain metastases
.
It can also effectively inhibit drug-resistant gene mutations and effectively solve many unmet clinical needs
.
In addition, according to Dr.
Li Jun, Chief Scientific Officer of Homo Health, TY-2136b also has a certain ability to penetrate the blood-brain barrier, which has potential advantages for patients with brain metastases
.
Figure 2: Sales of ilaprazole (unit: ten thousand yuan)
Source: Minet database
Livzon’s current major chemical drug Category 1 new drug is ilaprazole.
The tablet entered the National Medical Insurance Routine List in 2017.
It is now a Category B species in the 2021 National Medical Insurance List.
It is limited to duodenal ulcers and anti-inflammatory drugs.
Second-line medication for patients diagnosed with fluid esophagitis; injections entered the negotiation list in 2019, and are currently a category B species in the 2021 version of the National Medical Insurance Negotiation List, and are limited to peptic ulcer bleeding
.
The tablet entered the National Medical Insurance Routine List in 2017.
It is now a Category B species in the 2021 National Medical Insurance List.
It is limited to duodenal ulcers and anti-inflammatory drugs.
Second-line medication for patients diagnosed with fluid esophagitis; injections entered the negotiation list in 2019, and are currently a category B species in the 2021 version of the National Medical Insurance Negotiation List, and are limited to peptic ulcer bleeding
.
After entering the medical insurance catalogue, the innovative drug showed an explosive growth trend.
According to data from Minai.
com, in 2020, it will be used in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as China public medical institutions) terminals and cities in China.
The total sales of physical pharmacies have exceeded 2 billion yuan
.
According to data from Minai.
com, in 2020, it will be used in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as China public medical institutions) terminals and cities in China.
The total sales of physical pharmacies have exceeded 2 billion yuan
.
Medical insurance negotiations have gradually formed a "one-year talk" model, and the time for innovative drugs to enter medical insurance has been greatly shortened
.
At present, although Livzon’s LZ001 tablets are in the clinical stage, as China’s policies continue to increase, the outbreak period after the launch of innovative drugs is also worth looking forward to
.
.
At present, although Livzon’s LZ001 tablets are in the clinical stage, as China’s policies continue to increase, the outbreak period after the launch of innovative drugs is also worth looking forward to
.
Source: CDE official website, Minet database
The review data statistics are as of December 20, if there are any errors or omissions, please correct me
.
.
Note: Meinenet China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 cities and above cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
.
The above sales are calculated based on the average retail price of the product at the terminal
.
On December 17, Livzon Pharmaceutical Group submitted a clinical application for a new class 1 chemical drug LZ001 tablet, which is the first class 1 new drug declared by the company this year
.
Looking back on the previous years, after Livzon won the approval for the new category 1 drug of ilaprazole enteric-coated tablets in 2007, it also won the approval for the new category 2 drug of ilaprazole sodium for injection in 2017.
The performance of innovative drugs in the market has risen step by step, and has now become a large variety of more than 2 billion.
Livzon's re-attack on innovative drugs for chemical drugs has attracted market attention
.
.
Looking back on the previous years, after Livzon won the approval for the new category 1 drug of ilaprazole enteric-coated tablets in 2007, it also won the approval for the new category 2 drug of ilaprazole sodium for injection in 2017.
The performance of innovative drugs in the market has risen step by step, and has now become a large variety of more than 2 billion.
Livzon's re-attack on innovative drugs for chemical drugs has attracted market attention
.
Picture 1: Livzon's latest product status
Source: CDE official website
It is reported that LZ001 tablets are a kind of ROS1/NTRK/ALK multi-kinase small molecule inhibitor obtained by Livzon through Zhejiang Tongkang Medicine in 2020 (initial name is TY2136b project).
At that time, the pre-clinical research and development fee and down payment of this transaction The total amount of funds and milestone payments reached 159 million yuan
.
At that time, the pre-clinical research and development fee and down payment of this transaction The total amount of funds and milestone payments reached 159 million yuan
.
Pre-clinical studies have shown that TY-2136b has excellent curative effects on multiple targets of ROS1/NTRK/ALK.
It can also effectively inhibit drug-resistant gene mutations and effectively solve many unmet clinical needs
.
In addition, according to Dr.
Li Jun, Chief Scientific Officer of Homo Health, TY-2136b also has a certain ability to penetrate the blood-brain barrier, which has potential advantages for patients with brain metastases
.
It can also effectively inhibit drug-resistant gene mutations and effectively solve many unmet clinical needs
.
In addition, according to Dr.
Li Jun, Chief Scientific Officer of Homo Health, TY-2136b also has a certain ability to penetrate the blood-brain barrier, which has potential advantages for patients with brain metastases
.
Figure 2: Sales of ilaprazole (unit: ten thousand yuan)
Source: Minet database
Livzon’s current major chemical drug Category 1 new drug is ilaprazole.
The tablet entered the National Medical Insurance Routine List in 2017.
It is now a Category B species in the 2021 National Medical Insurance List.
It is limited to duodenal ulcers and anti-inflammatory drugs.
Second-line medication for patients diagnosed with fluid esophagitis; injections entered the negotiation list in 2019, and are currently a category B species in the 2021 version of the National Medical Insurance Negotiation List, and are limited to peptic ulcer bleeding
.
The tablet entered the National Medical Insurance Routine List in 2017.
It is now a Category B species in the 2021 National Medical Insurance List.
It is limited to duodenal ulcers and anti-inflammatory drugs.
Second-line medication for patients diagnosed with fluid esophagitis; injections entered the negotiation list in 2019, and are currently a category B species in the 2021 version of the National Medical Insurance Negotiation List, and are limited to peptic ulcer bleeding
.
After entering the medical insurance catalogue, the innovative drug showed an explosive growth trend.
According to data from Minai.
com, in 2020, it will be used in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as China public medical institutions) terminals and cities in China.
The total sales of physical pharmacies have exceeded 2 billion yuan
.
According to data from Minai.
com, in 2020, it will be used in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as China public medical institutions) terminals and cities in China.
The total sales of physical pharmacies have exceeded 2 billion yuan
.
Medical insurance negotiations have gradually formed a "one-year talk" model, and the time for innovative drugs to enter medical insurance has been greatly shortened
.
At present, although Livzon’s LZ001 tablets are in the clinical stage, as China’s policies continue to increase, the outbreak period after the launch of innovative drugs is also worth looking forward to
.
.
At present, although Livzon’s LZ001 tablets are in the clinical stage, as China’s policies continue to increase, the outbreak period after the launch of innovative drugs is also worth looking forward to
.
Source: CDE official website, Minet database
The review data statistics are as of December 20, if there are any errors or omissions, please correct me
.
.
Note: Meinenet China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 cities and above cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
.
The above sales are calculated based on the average retail price of the product at the terminal
.
On December 17, Livzon Pharmaceutical Group submitted a clinical application for a new class 1 chemical drug LZ001 tablet, which is the first class 1 new drug declared by the company this year
.
Looking back on the previous years, after Livzon won the approval for the new category 1 drug of ilaprazole enteric-coated tablets in 2007, it also won the approval for the new category 2 drug of ilaprazole sodium for injection in 2017.
The performance of innovative drugs in the market has risen step by step, and has now become a large variety of more than 2 billion.
Livzon's re-attack on innovative drugs for chemical drugs has attracted market attention
.
.
Looking back on the previous years, after Livzon won the approval for the new category 1 drug of ilaprazole enteric-coated tablets in 2007, it also won the approval for the new category 2 drug of ilaprazole sodium for injection in 2017.
The performance of innovative drugs in the market has risen step by step, and has now become a large variety of more than 2 billion.
Livzon's re-attack on innovative drugs for chemical drugs has attracted market attention
.
Picture 1: Livzon's latest product status
Source: CDE official website
It is reported that LZ001 tablets are a kind of ROS1/NTRK/ALK multi-kinase small molecule inhibitor obtained by Livzon through Zhejiang Tongkang Medicine in 2020 (initial name is TY2136b project).
At that time, the pre-clinical research and development fee and down payment of this transaction The total amount of funds and milestone payments reached 159 million yuan
.
Medicine Medicine MedicineAt that time, the pre-clinical research and development fee and down payment of this transaction The total amount of funds and milestone payments reached 159 million yuan
.
Pre-clinical studies have shown that TY-2136b has excellent curative effects on multiple targets of ROS1/NTRK/ALK.
It can also effectively inhibit drug-resistant gene mutations and effectively solve many unmet clinical needs
.
In addition, according to Dr.
Li Jun, Chief Scientific Officer of Homo Health, TY-2136b also has a certain ability to penetrate the blood-brain barrier, which has potential advantages for patients with brain metastases
.
It can also effectively inhibit drug-resistant gene mutations and effectively solve many unmet clinical needs
.
In addition, according to Dr.
Li Jun, Chief Scientific Officer of Homo Health, TY-2136b also has a certain ability to penetrate the blood-brain barrier, which has potential advantages for patients with brain metastases
.
Figure 2: Sales of ilaprazole (unit: ten thousand yuan)
Source: Minet database
Livzon’s current major chemical drug Category 1 new drug is ilaprazole.
The tablet entered the National Medical Insurance Routine List in 2017.
It is now a Category B species in the 2021 National Medical Insurance List.
It is limited to duodenal ulcers and anti-inflammatory drugs.
Second-line medication for patients diagnosed with fluid esophagitis; injections entered the negotiation list in 2019, and are currently a category B species in the 2021 version of the National Medical Insurance Negotiation List, and are limited to peptic ulcer bleeding
.
The tablet entered the National Medical Insurance Routine List in 2017.
It is now a Category B species in the 2021 National Medical Insurance List.
It is limited to duodenal ulcers and anti-inflammatory drugs.
Second-line medication for patients diagnosed with fluid esophagitis; injections entered the negotiation list in 2019, and are currently a category B species in the 2021 version of the National Medical Insurance Negotiation List, and are limited to peptic ulcer bleeding
.
After entering the medical insurance catalogue, the innovative drug showed an explosive growth trend.
According to data from Minai.
com, in 2020, it will be used in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as China public medical institutions) terminals and cities in China.
The total sales of physical pharmacies have exceeded 2 billion yuan
.
Hospital hospital hospital pharmacy pharmacy pharmacyAccording to data from Minai.
com, in 2020, it will be used in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as China public medical institutions) terminals and cities in China.
The total sales of physical pharmacies have exceeded 2 billion yuan
.
Medical insurance negotiations have gradually formed a "one-year talk" model, and the time for innovative drugs to enter medical insurance has been greatly shortened
.
At present, although Livzon’s LZ001 tablets are in the clinical stage, as China’s policies continue to increase, the outbreak period after the launch of innovative drugs is also worth looking forward to
.
.
At present, although Livzon’s LZ001 tablets are in the clinical stage, as China’s policies continue to increase, the outbreak period after the launch of innovative drugs is also worth looking forward to
.
Source: CDE official website, Minet database
Source: CDE official website, Minet database The review data statistics are as of December 20, if there are any errors or omissions, please correct me
.
.
Note: Meinenet China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 cities and above cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
.
The above sales are calculated based on the average retail price of the product at the terminal
.
